

AmBisome® (amphotericin B) - First-time generic

- On February 15, 2022, <u>Sun Pharmaceuticals launched</u> an <u>AB-rated</u> generic version of Astellas' Ambisome (amphotericin B) liposome for injection.
- AmBisome is approved for the following:
 - Empirical therapy for presumed fungal infection in febrile, neutropenic patients
 - Treatment of cryptococcal meningitis in HIV-infected patients
 - Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections and
 - Treatment of visceral leishmaniasis.
- Amphotericin B is also available generically as an <u>injection</u> and as branded <u>Abelcet</u>[®].
 - Amphotericin B is used to treat progressive, potentially life-threatening fungal infections.
 - Abelcet is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.